Respiratory Strategic Roundup exploring Developments and Competitive Shifts
Coverage Period: June 25–July 30, 2026
Introduction
The defining story of the reporting period was the widening of respiratory competition from individual drug launches to integrated portfolios spanning new mechanisms, expanded indications, differentiated delivery, and care infrastructure.
This shift was visible across pulmonary fibrosis, COPD, asthma, pulmonary arterial hypertension, and lung transplantation. Regulatory approvals created near-term commercial opportunities, while licensing, formulation innovation, and device development showed how companies are building positions across multiple stages of the patient journey. The strategic question is no longer only which therapy delivers clinical benefit, but which portfolio can combine efficacy with tolerability, convenience, market access, geographic reach, and system-level value.
Executive Summary
- Pulmonary fibrosis moved into a new commercialization phase. UK and European approvals of nerandomilast introduced a new oral mechanism for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Its tolerability profile and lack of routine liver monitoring may support differentiation, although reimbursement, treatment sequencing, and real-world persistence will determine market impact.
- COPD and asthma competition shifted toward portfolio breadth. AstraZeneca’s licensing of a late-stage PDE3/4 inhibitor and the European regulatory progress of Trixeo in asthma show how established respiratory companies are combining new mechanisms with indication expansion to strengthen franchise value.
- Convenience emerged as a central point of differentiation in pulmonary arterial hypertension. Insmed’s 12-month extension data for once-daily TPIP supported continued Phase III development and reinforced the commercial importance of reducing treatment burden. The open-label design means randomized confirmation remains essential.
- Respiratory innovation expanded beyond medicines. FDA approval of United Therapeutics’ LungFX device and UK authorization of lower-carbon beclometasone inhalers highlighted the growing role of infrastructure, device design, and environmental performance in respiratory-market strategy.
Watch the video summary
Strategic Perspective
New Pulmonary Fibrosis Therapies Shift Competition Toward Persistence and Treatment Sequencing
The UK and European approvals of nerandomilast represented the clearest near-term market development of the period. As an oral preferential PDE4B inhibitor with antifibrotic and immunomodulatory activity, the therapy adds a differentiated mechanism to the treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
Its strategic importance extends beyond clinical efficacy. Existing antifibrotic treatment can be limited by gastrointestinal side effects, monitoring burdens, and discontinuation. Nerandomilast’s reported tolerability profile and absence of a routine liver-monitoring requirement may support longer treatment duration and expand the number of patients able to remain on therapy.
The approvals also give Boehringer Ingelheim an opportunity to influence treatment sequencing and combination strategies. With an established position in fibrotic lung disease, the company can use physician relationships, market-access capabilities, and disease education to support adoption of the new mechanism.
The market implication is that competition in pulmonary fibrosis may increasingly center on persistence, ease of use, and evidence supporting placement within the treatment pathway. A therapy that slows lung-function decline but is easier to tolerate could alter prescribing behavior even without a dramatic efficacy advantage.
Key uncertainty: The pivotal studies met their primary lung-function endpoints, but key secondary composite endpoints were not met. Pricing, reimbursement, combination use, physician confidence, and real-world discontinuation rates will determine whether the regulatory milestone produces a meaningful commercial shift.
COPD PDE3/4 Development and Asthma Triple Therapy Strengthen Portfolio-Based Competition
Recent activity in COPD and asthma showed how leading respiratory companies are using both external innovation and lifecycle expansion to build more resilient portfolios.
AstraZeneca’s agreement for ex-China rights to TQC3721 adds a late-stage PDE3/4 inhibitor to a COPD pipeline that already includes multiple anti-inflammatory and immune-targeted approaches. The transaction indicates that the commercial emergence of Ohtuvayre has increased confidence in PDE3/4 inhibition as a viable COPD category. It also shows the value of licensing clinically advanced assets when speed to market matters.
TQC3721’s nebulized and dry-powder formulations could create options for different patient groups and care settings. AstraZeneca may also benefit from its established COPD commercial infrastructure and experience with inhaled therapies. However, positioning will depend on whether the asset can demonstrate a meaningful advantage in efficacy, dosing, formulation, or patient selection.
The positive European regulatory opinion for Trixeo in asthma supports the same portfolio logic. Extending a triple-combination inhaler from COPD into uncontrolled asthma could increase product lifecycle value, create commercial efficiencies, and provide another option for patients inadequately controlled on dual inhaled therapy.
The market implication is that respiratory leadership may depend less on a single blockbuster and more on the ability to offer multiple treatment approaches across disease severity and progression. Broad portfolios can strengthen physician access and contracting power, but they also increase the need for clear differentiation between products.
Key uncertainty: TQC3721 lacks direct comparative evidence against Ohtuvayre, while Trixeo will enter an asthma market shaped by dual inhalers, biologics, guidelines, and payer controls. Clinical relevance, rather than portfolio breadth alone, will determine adoption.
Once-Daily Inhaled Prostanoids Raise the Competitive Bar in Pulmonary Arterial Hypertension
Insmed’s 12-month open-label extension results for treprostinil palmitil inhalation powder supported the development case for a once-daily inhaled prostanoid in pulmonary arterial hypertension.
Patients who continued TPIP showed sustained improvements across exercise capacity, NT-proBNP, functional class, and REVEAL Lite 2.0 risk status. Patients who crossed from placebo also improved and reached similar outcomes by month 12. These findings add durability to the earlier clinical signal and support progression into Phase III development.
The strategic value lies in the relationship between efficacy and administration burden. Prostanoid treatment can be demanding, and a once-daily inhaled option could appeal to patients and physicians seeking a simpler long-term regimen. If confirmed, that convenience could become a meaningful commercial advantage in a market where adherence and treatment burden influence therapy choice.
TPIP may also have platform value beyond PAH because it is being studied across pulmonary hypertension associated with interstitial lung disease, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. Success in more than one indication could improve development efficiency and broaden the asset’s commercial role.
Key uncertainty: The extension study was open-label and had no concurrent control group. Secondary efficacy measures may overstate the true treatment effect, and safety, discontinuation, and dose tolerability require confirmation in the randomized Phase III PALM-PAH trial.
Lung Perfusion and Lower-Carbon Inhalers Expand Respiratory Strategy Beyond Drug Efficacy
Two developments showed that competitive advantage in respiratory care is extending into technology, infrastructure, and environmental performance.
FDA approval of United Therapeutics’ LungFX device supports centralized ex vivo lung perfusion for donor lungs that might otherwise go unused. The centralized model could allow transplant centers to access lung-assessment capabilities without building their own facilities. It also strengthens United Therapeutics’ position across pulmonary medicine, organ preservation, and future transplant-enabling technologies.
The potential market value lies in addressing a system-level constraint: the limited supply of usable donor lungs. A scalable centralized service could increase access to assessment technology and create a platform for additional organ-preservation capabilities.
The UK approval of beclometasone inhalers using the lower-carbon HFA-152a propellant reflects a different form of innovation. The therapeutic ingredient and indication remain unchanged, but the product offers a lower-emissions delivery system. This could matter as health systems incorporate environmental impact into procurement and manufacturers prepare for future propellant transitions.
These developments indicate that respiratory products may increasingly be evaluated on more than clinical efficacy. Operational value, environmental performance, manufacturing readiness, and compatibility with health-system priorities could affect competitive positioning.
Key uncertainty: LungFX carries important clinical-outcome warnings, including survival findings that did not meet a prespecified performance goal. Lower-carbon inhalers must still demonstrate that environmental differentiation translates into procurement preference, prescribing change, or commercial advantage.
Next Respiratory Strategic Watchpoints
- European pricing, reimbursement, and treatment-pathway positioning for nerandomilast in IPF and PPF.
- The global development strategy, formulation priorities, and regulatory timeline for TQC3721.
- Final European authorization and early commercial uptake of Trixeo in uncontrolled asthma.
- Randomized Phase III confirmation of TPIP’s efficacy, tolerability, and once-daily convenience.
- Early utilization, center adoption, and post-market outcome evidence for LungFX.
- The extent to which lower-carbon propellants influence inhaler procurement and portfolio conversion.
Respirtory Strategic Roundup: Key Takeaway
About LucidQuest
LucidQuest helps organizations anticipate change by identifying emerging signals, market shifts, and strategic opportunities.
Find more Strategic Roundups for multiple therapy areas here.
Contact us at: info@lqventures.com